Coagulation Disorders in Patients With Cirrhosis
Publication Date: September 24, 2021
Key Points
Key Points
- Significant alterations in laboratory parameters — such as platelet count (PLT) and prothrombin time/international normalized ratio (PT/INR) — routinely accompany cirrhosis.
- However, the risks of both bleeding and thrombosis are not accurately quantitated by standard testing in this population.
- The best strategies to identify patients at risk for bleeding or thrombosis, to provide appropriate prophylaxis in patients at risk for clinically significant bleeding, to screen for and treat portal vein thrombosis, and to prevent clinically significant thromboembolic events are currently unknown.
Diagnosis
...Diagn...
...Testing Strate...
...elastic Testing (VET)In patients wi...
...n patients with stable cirrhosis (...
...Portal Vein Thro...
...h cirrhosis, the AGA suggests against routine scr...
Treatment
...Treatme...
...Preproce...
...and/or Fresh Frozen Plasma (FFP)In p...
...hrombopoietin receptor agonist (TPO-Ras)In p...
...Venous Thromboembolism...
...talized patients with cirrhosis and who otherwis...
...Acute or Subacute Non-tumo...
...ents with cirrhosis and acute or subacute no...
...Atrial Fibrillati...
In patients with cirrhosis and atrial fib...
...Procedure Risk Stratification...